288383-20-0 Usage
Description
Cediranib, also known as AZD2171, is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases, which play a central role in vasculogenesis and angiogenesis. It is a small molecule drug that targets multiple receptor and non-receptor tyrosine kinases, including those in the platelet-derived growth factor, fibroblast growth factor, and endothelial growth factor receptor families. Cediranib effectively blocks tubule formation by human umbilical vein endothelial cells in vitro and prevents angiogenesis and xenograft tumor growth in vivo. Due to its ability to inhibit angiogenesis, Cediranib has potential use in a range of cancers.
Uses
Used in Oncology:
Cediranib is used as an anti-cancer agent for blocking angiogenesis, which is a critical process for tumor growth and progression. It has shown potential in the treatment of various cancers, including cervical cancer, by inhibiting VEGF-stimulated proliferation and KDR phosphorylation with IC50 values of 0.4 and 0.5 nM, respectively.
Used in Molecular Targeted Drug Research:
Cediranib is used as a molecular targeted drug in the study of cervical cancer, where it has shown promise in understanding tumor biology and the development of personalized treatment strategies.
Used in Clinical Applications:
Cediranib is used in clinical applications to evaluate its efficacy and safety in cancer treatment. The drug's ability to inhibit a variety of receptor and non-receptor tyrosine kinases makes it a valuable candidate for further research and development in oncology.
Used in Biomarker Research:
Cediranib is used in the study of correlative biomarkers to better understand tumor biology and predict treatment response. This research can help identify patients who are more likely to benefit from Cediranib treatment and improve the overall effectiveness of cancer therapy.
Anticancer drugs
Cediranib is an oral anticancer drug , it is successfully developed by the US AstraZeneca company , its trade name is recentin, this product is an efficient VEGFR tyrosine kinase inhibitor, it is capable of inhibiting all known VEGFR tyrosine kinases ( including VEGFR-1, VEGFR-2, VEGFR-3, and PDGFR). Cediranib can inhibit VEGF-induced angiogenesis, neovascularization survival and human tumor xenograft cell growth.Clinical trail phase I for non-small cell lung cancer (abbreviated NSCLC) patients shows that cediranib in combination with PC programs has a significant antitumor effect . Clinical trail phaseⅡ/Ⅲ BR24 focuses on using cediranib 30mg as a first-line treatment of NSCLC ,which demonstrates that it has anti-tumor effect, but it has a higher incidence of adverse events, including diarrhea, dehydration, hand-foot syndrome, hypertension and neutropenia disease. Therefore, there is the decision to stop clinical trials. Repeated assessments about toxicity and dose of the combination of drugs suggest that part of the adverse effects are dose-related , dose reduction may be tried to improve drug tolerance. In view of this conclusion, in 2009, the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) launched a cediranib clinical trail phase Ⅲ (BR29) for progressive NSCLC patients , the dose was adjusted to 20mg. The results have not been reported.
In 2009 ,European Society for Medical Oncology (ESMO) Annual report which is about cediranib treatment of metastatic renal cell carcinoma (referred mRCC) clinical trail phase II shows that cediranib treatment group tumor volume reducing rate is higher than the placebo group. Zurita tested Cediranib pretreatment serum cytokines and angiogenic factors ,and found that patients having low IL-10, VEGF, PIGF, SCF and MIG concentration during baseline time , have the more obvious tumor volume reduction after treatment.
The above information is edited by the lookchem of Tian Ye.
references
[1] wedge sr, kendrew j, hennequin lf, valentine pj, barry st, brave sr, smith nr, james nh, dukes m, curwen jo, chester r, jackson ja, boffey sj, kilburn ll, barnett s, richmond gh, wadsworth pf, walker m, bigley al, taylor st, cooper l, beck s, jürgensmeier jm, ogilvie dj. azd2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. cancer res. 2005 may 15;65(10):4389-400.
Check Digit Verification of cas no
The CAS Registry Mumber 288383-20-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,8,8,3,8 and 3 respectively; the second part has 2 digits, 2 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 288383-20:
(8*2)+(7*8)+(6*8)+(5*3)+(4*8)+(3*3)+(2*2)+(1*0)=180
180 % 10 = 0
So 288383-20-0 is a valid CAS Registry Number.
InChI:InChI=1/C25H27FN4O3/c1-16-12-17-19(29-16)6-7-21(24(17)26)33-25-18-13-22(31-2)23(14-20(18)27-15-28-25)32-11-5-10-30-8-3-4-9-30/h6-7,12-15,29H,3-5,8-11H2,1-2H3
